Neurology Specific Literature Search   
 
[home][thesaurus]
    

Enter your terms
above and click
the 'Search' button.
Showing articles 0 to 50 of 107 Next >>

Filter Applied: efficacy (Click to remove)

Evidence-based Guideline Update: NSAIDs and Other Complementary Treatments for Episodic Migraine Prevention in Adults
Neurol 78:1346-1353, Holland,S.,et al, 2012

Evidence-based Guideline Update: Pharmacologic Treatment for Episodic Migraine Prevention in Adults
Neurol 78:1337-1345, Silberstein,S.D.,et al, 2012

Botulinum Toxin A for Prophylactic Treatment of Migraine and Tension Headaches in Adults
JAMA 307:1736-1745, Jackson,J.L.,et al, 2012

Reversible Cerebral Vasoconstruction Syndromes
Arch Neurol 68:1005-1012,976, Singhal, A.B.,et al, 2011

Treatment Modalities and Outcomes in Brainstem Cavernous Malformations: A Large Multicenter Observational Cohort Study
Stroke 55:1151-1160, Lu,J.,et al, 2024

Atogepant for the Preventive Treatment of Chronic Migraine (PROGRESS): A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial
Lancet 402:775-785, Pozo-Rosich,P.,et al, 2023

Lenvatinib Therapy for Advanced Thyroid Cancer: Real-Life Data on Safety, Efficacy, and Some Rare Side Effects
JENDSO 6:1-7, Hamidi, S.,et al, 2022

The SANAD II study of the Effectiveness and Cost-Effectiveness of Levetiracetam, Zonisamide, or Lamotrigine for Newly Diagnosed Focal Epilepsy: An Open-Label, Non-Inferiority, Multicentre, Phase 4, Randomised Controlled Trial
Lancet 397:1363-1374, Marson, A.,et al, 2021

The SANAD II Study of the Effectiveness and Cost-Effectiveness of Valproate Versus Levetiracetam for Newly Diagnosed Generalised and Unclassifiable Epilepsy: An Open-Label, Non-Inferiority, Multicentre, Phase 4, Randomised Controlled Trial
Lancet 397:1375-1386, Marson, A.,et al, 2021

Acute Treatment for Migraine
JAMA 325:2346-2347, Burch, R. & Rayhill, M., 2021

Atogepant for the Preventive Treatment of Migraine
NEJM 385:695-706, Ailani,J.,et al, 2021

Relapse of Severe Neurosarcoidosis with Switch from Originator Infliximab to Biosimilar
Neurol 94:991-993, Kidd, D.P.,et al, 2020

One-Year Sustained Efficacy of Erenumab in Episodic Migraine
Neurol 95:e469-e479, Goadsby, P.J.,et al, 2020

Efficacy and Safety of Adjunctive Lacosamide in the Treatment of Primary Generalised Tonic-Clonic Seizures: A Double-Blind, Randomised, Placebo-Controlled Trial
JNNP 91:1067-1075, Vossler, D.G.,et al, 2020

Erenumab in Chronic Migraine
Neurol 92:e2250-e2260, Lipton, R.B.,et al, 2019

Remigepant, an Oral Calcitonin Gene-Related Peptide Receptor Antagonist, for Migraine
NEJM 381:142-149, Lipton, R.B.,et al, 2019

Trial of Galcanezumab in Prevention of Episodic Cluster Headache
NEJM 381:132-141, Goadsby, P.J.,et al, 2019

Pharmacologic Treatment for Pediatric Migraine Prevention
Neurol 93:500-509, Oskoui, M.,et al, 2019

Fremanezumab versus Placebo for Migraine Prevention in Patients with Documented Failure to Up to Four Migraine Preventive Medication Classes (FOCUS): A Randomised, Double-Blind, Placebo-Controlled, Phase 3� Trial
Lancet 394:1030-1040, Ferrari, M.D.,et al, 2019

Targeting Calcitonin Gene-Related Peptide: A New Era in Migraine Therapy
Lancet 394:1765-1774, Charles, A. & Pozo-Rosich, P., 2019

Ubrogepant for the Treatment of Migraine
NEJM 381:2230-2241, Dodick, D.W.,et al, 2019

Aminophylline for treatment of postdural puncture headache
Neurol 90:e1523-e1529, Wu, C.,et al, 2018

Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome
NEJM 378:1888-1897, Devinsky, O.,et al, 2018

Efficacy and Tolerability of the new antiepileptic drugs II: Treatment-resistant epilepsy
Neurol 91:82-90, Kanner, A.M.,et al, 2018

Efficacy and Tolerability of the new antiepileptic drugs I: Treatment of new-onset epilepsy
Neurol 91:74-81, Kanner, A.M.,et al, 2018

Noninvasive Vagus Nerve Stimulation as Acute Therapy for Migraine
Neurol 91:e364-e373, Tassorelli,C., et al, 2018

Efficacy and Tolerability of Erenumab in Patients with Episodic Migraine in Whom Two-of-Four Previous Preventive Treatments were Unsuccessful: A Randomised, Double-Blind, Placebo-Controlled, Phase 3b Study
Lancet 392:2280-2287,2241, Reuter, U.,et al, 2018

Galcanezumab in Chronic Migraine
Neurol 91:e2211-e2221, Detke, H.C.,et al, 2018

Lasmiditan is an Effective Acute Treatment for Migraine
Neurol 91:e2222-e2232, Kuca, B.,et al, 2018

A Randomized Trial of Telemedicine Efficacy and Safety for Nonacute Headaches
Neurol 89:153-162, Muller, K.I.,et al, 2017

CGRP - The Next Frontier for Migraine
NEJM 377:2190-2191, Hershey, A.D., 2017

Practice Guideline Update Summary: Botulinum Neurotoxin for the Treatment of Blepharospasm, Cervical Dystonia, Adult Spasticity, and Headache
Neurol 86:1818-1826, Simpson, D.M.,et al, 2016

Prophylactic Antiepileptics and Seizure Incidence Following Subarachnoid Hemorrhage
Stroke 47:1754-1760, Panczykowski, D.,et al, 2016

Resective Epilepsy Surgery for Drug-Resistant Focal Epilepsy
JAMA 313:285-293, Jobst, B.C. & Cascino, G.D., 2015

Anesthetic Drugs in Status Epilepticus: Risk or Rescue?
Neurol 82:656-664, Sutter, R.,et al, 2014

Drug Treatment of Epilepsy in Adults
BMJ 348:g2546, Schmidt, D. & Schachter, S.C., 2014

Triptans for Symptomatic Treatment of Migraine Headache
BMJ 348:g2285, Pringsheim, T. & Becker, W.J., 2014

Systematic Review: Efficacy and Safety of Medical Marijuana in Selected Neurologic Disorders
Neurol 82:1556-1563, Koppel, B.S.,et al, 2014

Effect of Rituximab in Patients with Leucine-Rich, Glioma-Inactivated 1 Antibody-Associated Encephalopathy
JAMA Neurol 71:896-900, Irani, S.R.,et al, 2014

Evidence-based Guideline: Treatment of Parenchymal Neurocysticercosis
Neurol 80:1424-1429, Baird, R.,et al, 2013

Evidence-Based Guideline Update: Vagus Nerve Stimulation for the Treatment of Epilepsy
Neurol 81:1453-1459, Morries, G.L.,et al, 2013

Continuous and Routine EEG in Intensive Care
Neurol 81:2002-2008, Ney, J.P.,et al, 2013

Evidence-based Guideline: Antiepileptic Drug Selection for People with HIV/AIDS
Neurol 78:139-145, Birbeck,G.L.,et al, 2012

Therapeutic Devices for Epilepsy
Ann Neurol 71:157-168, Fisher,R.S., 2012

Radiosurgery for Unruptured Cerebral Arteriovenous Malformations
Neurol 78:1292-1298, Yang,S.Y.,et al, 2012

Time-Dependent Test Characteristics of Head Computed Tomography in Patients Suspected of Nontraumatic Subarachnoid Hemorrhage
Stroke 43:2115-2119, Backes, D.,et al, 2012

Seizure risk with AVM Treatment or Conservative Management
Neurol 79:500-507, Josephson, C.B.,et al, 2012

Results of Phase 2 Safety and Feasibility Study of Treatment with Levetiracetam for Prevention of Posttraumatic Epilepsy
Arch Neurol 69:1290-1295, Klein, P.,et al, 2012

Early Surgical Therapy for Drug-Resistant Temporal Lobe Epilepsy
JAMA 307:922-930, Engel, J.,et al, 2012



Showing articles 0 to 50 of 107 Next >>